Using advanced imaging to predict outcomes in early-stage triple negative breast cancer

Who could benefit from this research

What this research studies

This research investigates the use of Label-Free Optical Redox Imaging (ORI) to assess the metabolic characteristics of early-stage triple negative breast cancer (TNBC) tumors. By analyzing the intrinsic fluorescence signals of specific molecules within the tumor, the study aims to identify different metabolic subtypes that may influence disease progression. This innovative imaging technique offers a high-resolution, three-dimensional view of the tumor's microenvironment, potentially providing more accurate prognostic information than traditional methods. Patients with TNBC may benefit from this approach by receiving tailored treatment plans based on their tumor's unique metabolic profile.

Why it matters

Where this research is happening

• University of Pennsylvania
  Philadelphia, United States Active

Researchers

• Principal investigator: Li, Lin Z — University of Pennsylvania
• Study coordinator: Li, Lin Z

Related research

Other NIH-funded projects on the same topics.

• Label-Free Optical Redox Imaging to Predict Outcomes in Early-Stage Triple-Negative Breast Cancer

  A new imaging approach uses intrinsic signals to spot metabolic differences in untreated early-stage TNBC tumors to help predict how the cancer may behave.

  NIH research University of Pennsylvania · Philadelphia, United States · NIH-11402679

• High-resolution label-free imaging to predict outcomes in early triple-negative breast cancer

  This work uses a special label-free imaging method to read tiny metabolic differences inside early-stage triple-negative breast tumors to help predict the chances of the cancer coming back.

  NIH research University of Pennsylvania · Philadelphia, United States · NIH-11161469

• Genomic study to understand how genetics and epigenetics shape triple-negative breast cancer in African ancestry

  This study looks at how inherited genes and gene activity affect triple-negative breast cancer in people of African ancestry to better understand why outcomes can be worse.

  NIH research Tuskegee University · Tuskegee Institute, United States · NIH-11621786

• Co-Targeting IL-6 and CDK4/6 to Prevent TNBC in Women Veterans

  A study aims to block two cancer-promoting pathways (IL-6 and CDK4/6) to prevent or reduce progression of triple-negative breast cancer in women veterans.

  NIH research Baltimore VA Medical Center · Baltimore, United States · NIH-11608792

• Linking heavy metal exposure to a tougher breast cancer type (TNBC)

  Aimed at understanding how heavy metals like cadmium might trigger a dangerous breast cancer type (TNBC) in people, especially those with BRCA1 risk, to identify possible future treatment strategies.

  NIH research University of Louisville · Louisville, United States · NIH-11567535

• Dormancy in Triple-Negative Breast Cancer: How Liver and Skin Metastases Go Quiet or Reactivate

  Researchers will study how dormant cancer cells in liver and skin metastases of triple-negative breast cancer become quiescent or wake up, using organ-on-chip models and single-cell analysis to map chromatin states.

  NIH research Massachusetts Institute of Technology · Cambridge, United States · NIH-11531542

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.